-0.85%
Today
Loading 1D prices…
Company profile
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Miami, FL, United States
Fiscal year end
1231
CIK
1971532
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ALDXAldeyra Therapeutics Inc. Common Stock | $80.8M | $0.00 | — | -$0.56 | -8.22% | Buy |
| RNXTRenovoRx Inc. Common Stock | $79.4M | $1.1M | -994.48% | -$0.32 | -0.56% | Buy |
| MAIAMAIA Biotechnology Inc. Common Stock | $79.1M | $0.00 | — | -$0.70 | -1.53% | Buy |
| OSTXOS Therapies Incorporated Common Stock | $78.6M | $0.00 | — | -$0.98 | -7.69% | Buy |
| IBIOiBio Inc. Common Stock | $77.5M | $100K | -33044.00% | -$0.32 | -0.38% | Buy |